Blastic Plasmacytoid Dendritic Cell Neoplasm Market

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy of the bone marrow and blood that can affect other organs such as the lymph nodes, spleen, central nervous system, and skin. In fact, skin lesions are present in most patients with BPDCN. These skin lesions are often a deep purple color, and patients often develop multiple lesions.
Although BPDCN occurs more frequently in the elderly, the tumor may occur in patients of any age, including pediatric patients.

More men than women are diagnosed with BPDCN (~3:1 ratio), and it is most common in patients aged 60 years and older.

According to the Leukemia and Lymphoma Society, BPDCN constitutes less than 1% of all hematologic malignancies, resulting in an estimated 1,000 to 1,400 cases occurring annually in the US and Europe combined.

90% of patients with BPDCN present with asymptomatic skin lesions – and early recognition can be challenging due to overlapping features with other benign and malignant disorders.

The key pharmaceutical Companies in the Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) market includes:
Immunogen
MustangBio
Abbvie
Stemline Therapeutics
Cellectis
Xencor
and many others

For more detailed information on Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Market, visit:
https://www.delveinsight.com/report-store/blastic-plasmacytoid-dendritic-cell-neoplasm-bpdcn-market